COVID-19 Vaccines: Regulation, Allocation, & Hesitancy


With several COVID-19 vaccines now making their way toward marketing approval, a number of difficult questions loom. Who should have access to the first available doses? How will companies and regulators assess safety and efficacy, including over the long term? And what does research say about the best ways for public health experts—and journalists—to communicate about the benefits and risks of COVID-19 vaccination? SciLine's on-the-record briefing addressed these issues and provided journalists with an opportunity to ask questions.

This article was published on
December 3, 2020

This explainer is more than 90 days old. Some of the information might be out of date or no longer relevant. Browse our homepage for up to date content or request information about a specific topic from our team of scientists.


What our experts say

Context and background


Media briefing

  • Dr. Michele Andrasik, Fred Hutchinson Cancer Research Center
  • Prof. R. Alta Charo, University of Wisconsin at Madison
  • Dr. Margaret “Peggy” Hamburg, former Commissioner, U.S. Food and Drug Administration
  • SciLine Director Rick Weiss will moderate the briefing.
  • Media Release

    Expert Comments: 

    No items found.


    No items found.